Inactive Instrument

VIVUS, Inc.

VVUSQ

US9285513084

VIVUS INC : Other Events, Financial Statements and Exhibits (form 8-K)

January 07, 2020 at 07:37 am EST

Item 8.01. Other Events

On January 7, 2020, VIVUS, Inc. issued a press release titled "New Data Further Demonstrate Effectiveness of VIVUS' Qsymia as a Weight Management Tool." A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits






(d)    Exhibits.



Exhibit No.                 Description

  99.1          Press Release dated January 7, 2020.

Latest news about VIVUS, Inc.

VIVUS LLC Announces It Will Provide Telehealth to Patients Through an Enhanced 'Engage' Program in Collaboration with UpScriptHealth	Apr. 22	CI
VIVUS LLC Announces Positive Topline Data from a Post-Marketing Study to Evaluate the Effect of QSYMIA	Nov. 28	CI
VIVUS, Inc. Promotes Santosh T. Varghese to President VIVUS Global Pharmaceutical Development	23-01-10	CI
FDA Approves VIVUS LLC's QSYMIA® for the Treatment of Obesity in Adolescents Ages 12-17	22-07-20	CI
VIVUS, Inc. Emerged from Bankruptcy	20-12-10	CI
Revised Second Amended Reorganization Plan & Disclosure Statement Approved for VIVUS, Inc.	20-12-10	CI
First Motion for Exclusivity Period Extension Approved For VIVUS, Inc.	20-11-16	CI
Second Amended Joint Pre-Packaged Reorganization Plan Filed by VIVUS, Inc.	20-11-10	CI
First Motion for Exclusivity Period Extension Filed by VIVUS, Inc.	20-11-03	CI
Motion for Asset Sale Filed by VIVUS, Inc.	20-10-20	CI
First Amended Joint Pre-Packaged Reorganization Plan Filed by VIVUS, Inc.	20-08-18	CI
VIVUS, Inc.(NasdaqGS:VVUS) dropped from S&P TMI Index	20-07-10	CI
Motion for Joint Administration Approved for VIVUS, Inc.	20-07-10	CI
Combined Hearing for Disclosure Statement and Plan Approved for VIVUS, Inc.	20-07-10	CI
Health Care Flat As Growth Investors Seek Out Tech -- Health Care Roundup	20-07-08	DJ
VIVUS, Inc. Appoints Jill Frizzley as a Independent Director of the Company	20-07-07	CI
VIVUS, Inc. Filed for Bankruptcy	20-07-07	CI
Motion for Joint Administration Filed by VIVUS, Inc.	20-07-07	CI
Joint Pre-Packaged Reorganization Plan and Disclosure Statement Filed by VIVUS, Inc.	20-07-07	CI
VIVUS, Inc.(NasdaqGS:VVUS) dropped from Russell Microcap Index	20-06-26	CI
VIVUS, Inc.(NasdaqGS:VVUS) dropped from Russell Microcap Value Index	20-06-26	CI
VIVUS, Inc.(NasdaqGS:VVUS) dropped from Russell Microcap Growth Index	20-06-26	CI
VIVUS, Inc. Contemplates Bankruptcy	20-06-02	CI
Transcript : VIVUS, Inc., Q1 2020 Earnings Call, May 06, 2020	20-05-06
Vivus, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-06	CI

Chart VIVUS, Inc.

Duration

Period

More charts

Company Profile

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.83%	653B
NOVO NORDISK A/S	+27.00%	556B
JOHNSON & JOHNSON	-6.76%	354B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+3.00%	296B
ASTRAZENECA PLC	+13.09%	233B
NOVARTIS AG	+5.46%	201B
ROCHE HOLDING AG	-9.61%	193B
AMGEN INC.	-6.26%	144B

Other Pharmaceuticals